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Abstract
One of the great  challenges in the pharmaceutical  industry is  the search for more
efficient and cost-effective ways to store and deliver existing drugs. Bio-inspired metal-
organic frameworks (BioMOFs) are groundbreaking materials that have recently been
explored for drug storage, delivery and controlled release as well as for applications in
imaging  and  sensing  for  therapeutic  and  diagnostic.  This  review presents  a  brief
overview on these materials, and by alluding to a few reported examples, it intends to
clearly show the extremely important role that BioMOFs have been playing in the
pharmaceutical field.
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1. Introduction
The development of new solid forms of pharmaceuticals is of utmost importance in modern
science as they present a single opportunity to modify the properties of active pharmaceutical
ingredients (API) without interfering with its biological role. The influence of the crystal forms
is very wide and diverse, changing not only the solid-state characteristics (density, habit, shape,
colour, stability, melting point) but also properties that might affect their function (dissolu‐
tion rate, solubility, stability to temperature and humidity, thermal properties, moisture uptake,
bioavailability, pharmacokinetics) and even some industrial aspects of formulation (flowabil‐
ity, mixability, stress stability, granulation, encapsulation, tabletting). The combination of crystal
engineering and supramolecular chemistry principles allows the design and synthesis of smartly
designed drugs with tailor-made properties, keeping their pharmacological properties, and
thus presenting major advantages, including reduced time for introduction in the market [1–6].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Consequently, the synthesis of new crystal forms evolved tremendously in the last decade,
and the interest of pharmaceutical companies in the appearance/disappearance of new solid
forms of APIs has vastly increased. Polymorphs, hydrates and salts of drugs are long-known
forms with recognized impact in their properties. Cocrystals represent a more recent class of
crystal forms that own particular scientific and regulatory advantages (FDA guidance is
already available and cocrystals are now being commercialized as drugs in some countries).
Many examples show their relevance in the pharmaceutical industry, most of them by
enhancing stability, solubility and/or bioavailability of known drugs [7–20].
Likewise, nanoporous materials recently became of pertinent use in the medicinal and
pharmacological fields for drug storage, delivery and controlled release in addition to
applications in imaging and sensing for therapeutic and diagnostic [21–34]. Particularly, metal
organic frameworks (MOFs) have generated large interest owing to their versatile architectures
[35] and their promising applications not only in ion exchange, adsorption and gas storage [36–
41], separation processes [42], heterogeneous catalysis [43, 44], polymerization reactions [45,
46], luminescence [47], non-linear optics [48] and magnetism [49], but also as drug carriers,
systems for drug delivery [22, 23, 50, 51], contrast agents for magnetic resonance imaging (MRI)
[21] and systems with potential use in other biomedical applications [23].
Up to now, drug delivery from porous solids has been achieved by encapsulation in mesopo‐
rous silicas or zeolites, methods that are strongly dependent on the pore size and on the host-
guest interactions. Both hypotheses suffer from important drawbacks: low drug-storage
capacity, too rapid delivery and solid degradation that brings toxicity concerns [23, 25, 26, 28,
29, 52]. Extended metal-ligand networks with metal nodes and bridging organic ligands such
as coordination networks, porous coordination networks (PCNs), porous coordination
polymers (PCPs) and MOFs have attracted great attention in the last years [24, 25, 28, 53, 54].
Particularly, MOFs with biological-friendly composition emerged as new drug carriers capable
of tackling these problems [21, 23, 25, 26, 28, 29, 55, 56].
In fact, MOFs are among the most exciting architectures in nanotechnology and are defined as
hybrid self-assemblies of metal ions or metal clusters (coordination centres) and organic
fragments (linkers). They exhibit some of the highest porosities known, turning them into ideal
materials for capture, storage and/or delivery applications [21, 24–26, 29, 54, 57]. Compared to
other nanocarriers, MOFs are candidates to extensive applications since they combine high
pore volume with a regular porosity, and the presence of tuneable organic groups allows an
easy modulation of the framework as well as of the pore size [22, 24–26].
The first families of MOFs considered as potential drug delivery systems were the coordination
polymers from Oslo (CPO), such as CPO-27(Mg) [58] built up from magnesium coordination
polymers, and the materials of Institute Lavoisier (MIL) [22]. Horcajada et al. [22, 23] prepared
MIL-100 (with trimesic acid) and MIL-101 (with terephthalic acid) applied for the delivery of
ibuprofen in the gastrointestinal tract, exhibiting high drug-storage capacity and a complete
drug-controlled release under physiological conditions [22, 23]. Less toxic systems, using iron
and more flexible MILs, are under study [25], and the first biodegradable therapeutic MOF,
BioMIL-1, was reported by Miller et al. in 2010 [27]. The large breathing effect that MOFs can
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attain is another particularly interesting feature for potential applications in drug delivery [54,
59, 52].
Zeolite-like MOFs (ZMOFs) are a unique subset of MOFs with exceptional characteristics
arising from the periodic pore systems and distinctive cage-like cavities, in conjunction with
modular intra- and/or extra-framework components [60–62]. Zeolitic imidazolate frameworks
(ZIFs) are a special class of ZMOFs comprising imidazolate linkers and metal ions. ZIFs
simultaneously have the following characteristics of MOFs and zeolites, combining the
advantages of both: ultrahigh surface areas, unimodal micropores, high crystallinity, various
functionalities and exceptional thermal and chemical stabilities, making them very promising
for biomedical applications [63, 64]. Several studies describe the successful incorporation of
anticancer drugs into ZIF-8 with positive results for the controlled pH-sensitive drug release
and fluorescence imaging [65–69]. Also caffeine was already encapsulated into ZIF-8 showing
a controlled release [70, 71].
The scope of this brief review focuses on presenting some aspects on the BioMOFs preparation,
and a few examples of promising bioapplications of MOFs, including ZIFs.
2. Building bio-inspired MOFs
2.1. Design
The use of porous solids for biomedical applications requires a biological friendly composition,
making compulsory the use of metals and linkers with acceptable toxicity [28].
When designing BioMOFs, the decision to exclude one linker and/or metal depends on several
parameters: application, balance between risk and benefit, degradation kinetics, biodistribu‐
tion, accumulation in tissues and organs as well as body excretion [21, 23, 25, 26, 28, 55, 56].
Both exogenous (not intervening in the body cycles) and endogenous (constitutive part of body
composition) linkers have been used in MOF synthesis for drug delivery, with the first group
having a higher prevalence [21, 25–29, 57]. It is also worth noting that if the therapeutic
molecule is directly used as a linker, no large pores are required and the release of the drug
molecule is achieved directly through the degradation of the solid, without any side effects
arising from the release of a non-active ligand [26, 52].
Different methods have been explored to design BioMOFs, including ZMOFs, from which we
highlight the molecular building block (MBB), supermolecular building block (SBB) and
supermolecular building layer (SBL) approaches. Also, a brief allusion to the influence that
computational simulations may have in building and studying BioMOFs is made.
2.1.1. Molecular building block (MBB), supermolecular building block (SBB) and supermolecular
building layer (SBL) approaches
To construct a MOF, it is necessary to make a pre-selection of building blocks that would give
the desired structural and geometrical information for a given underlying network—molec‐
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ular building block approach (MBB) [72]. The prerequisites for the successful implementation
of this approach are (a) selection of an ideal blueprint net exclusive for the assembly of its
corresponding basic building units and (b) isolation of the reaction conditions that allow the
formation of the desired MOF. Simple MBBs based on simple organic ligands or polynuclear
clusters are often limited in terms of connectivity [72]. To overcome this issue, two conceptual
approaches were recently implemented to facilitate the design and deliberate construction of
MOFs: supermolecular building block (SBB) and supermolecular building layer (SBL). These
approaches allow the rational design of made-to-order MOFs [73].
The SBB approach consists of using metal-organic polyhedral (MOPs) as SBBs in building an
MOF, presenting great potential to control the targeted framework. To obtain the desired
topology, the MOP must have the correct geometrical information and peripheral points of
extension (connectivity). The prerequisites for this approach are (a) a blueprint net with
minimal edge transitivity, preferably singular, exclusive for the assembly of given building
units, and not susceptible to self-interpenetration upon net expansion and/or decoration and
(b) reaction conditions that allow the formation of the SBB in situ.
The SBL is based on the use of 2-periodic MOF layers (SBLs) as building blocks for the desired
functional 3-periodic porous MOFs. This implies the chemical cross-linking of layers via
accessible bridging sites on the layers, such as open metal sites or functionalized positions on
the organic linker, whose judicious selection is mandatory. This approach, in principle, allows
to predict MOFs with tuneable cavities, the endless expansion of confined space (as cavities
and pores), and its modularity further permits an easy functionalization and introduction of
additional functionalities [74] to aim specific applications. The prerequisites for this approach
are (a) a blueprint net with minimal edge transitivity, rather singular, exclusive for the
particular pillaring of the given building units and (b) the reaction conditions to allow the
consistent formation of the SBL in situ.
2.1.2. Screening using simulations
Systematic studies relating MOF structures with their performance in drug delivery is crucial
for the identification of promising structures. Molecular simulations are a mean that can be
explored to seek for the optimal structure for a given application. The grand canonical Monte
Carlo (GCMC) simulation is the preferred method for simulating adsorption in porous
materials and for explaining and predicting new results. However, the simulation in the case
of large guest molecules is difficult and that justifies the limited number of studies on drug-
porous solid systems [75].
Fatouros et al. reported the use of molecular dynamics to study the diffusion properties of
salbutamol and theophylline in the zeolite BEA, an indication that this method can be used for
screening purposes on zeolite-drug systems [76].
Regarding MOFs, very few computational studies are reported and those are focused on one
or more structures simultaneously, limiting the possibility of correlating drug delivery
performance with structural features. A combined experimental and computational study of
three MOFs for the drug delivery of 5-fluorouracil was recently presented, in which GCMC
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simulations were used to investigate the interactions between the drug and the porous cage
[77]. Density functional theory (DFT) calculations have been applied to identify the most
favourable conformations and adsorption sites of ibuprofen and busulfan on MIL-53(Fe) [78].
Quantitative structure-activity relationship (QSAR) models were used to rationalize the
experimental uptake of caffeine as model in a series of MIL-88B(Fe) materials with different
functional moieties [79]. The energetics and dynamics of ibuprofen in MIL-101 were also
studied recurring to simulated annealing followed by DFT of one single ibuprofen molecule
to study the preferential adsorption sites [56].
Also worth mentioning an extensive study on GCMC simulations to screen a series of bio-
compatible MOFs as carriers of ibuprofen has been reported. Simulations include micropo‐
rous, mesoporous and nanoporous MOFs and have shown to be a successful pathway to
predict the drug adsorption properties of porous adsorbents. Furthermore, this work proposes
new tools that allow the study of new porous materials as potential drug carriers prior to
experiment [75].
2.2. Synthesis
MOFs are still widely synthesized using solvo/hydrothermal techniques, the most common
methods to obtain coordination networks [21, 25, 28, 29]. Nevertheless microemulsion
synthesis [80] is also a typical method and interesting alternatives are being used based on
environmental-friendly synthetic routes: ionothermal [81], microwave, ultrasound-assisted,
and sonochemical synthesis [21, 25, 28], as well as mechanochemistry [82, 83]. The synthesis
of this type of compounds has been reviewed several times [63, 84, 85] and therefore only brief
details on each technique are presented herein.
The solvo/hydrothermal synthesis involves polar solvents under moderate to high pressures
and temperatures. This method often requires toxic solvents such as DMF, and its use is limited
by safety and time-consuming reasons. Alternative techniques allow higher efficiencies, have
lower energy costs and have less impact in the environment [86].
Microemulsion synthesis is based on thermodynamically stable dispersions of two immiscible
liquids in the presence of an emulsifier or surfactant (i.e., microemulsions). This technique
confines the synthesis of MOFs to the nanoscale and offers the possibility of tuning the size.
The disadvantages of the microemulsion approach include poor yields, reproducibility issues,
usage of highly toxic surfactants and solvents that strongly limit biomedical applications and
the possible decrease of the sorption capacity due to the combination of surfactants with highly
porous structures [80, 86].
Ionothermal synthesis requires the use of green solvents such as ionic liquids and eutectic
mixtures (a special type of ionic liquid) to obtain MOFs and it can be performed in open air.
These solvents act both as solvents and templates to avoid the competition interactions
between the solvent framework and the template framework that are present in the solvo‐
thermal methods [63, 81].
Microwave and ultrasound-assisted syntheses usually lead to the fast crystallization of MOFs
and are considered green methods. In the case of microwaves, the heating involved in the
Bio-Inspired Metal-Organic Frameworks in the Pharmaceutical World: A Brief Review 5139
http://dx.doi.org/10.5772/64027
process favours a rapid and uniform nucleation process, which results into a more homoge‐
neous particle size distribution. Regarding ultrasounds, it has shown to be a highly efficient
method [86].
Sonochemical synthesis or sonocrystallization method not only promotes the nucleation
process but also stimulates the homogeneity of the nucleation, what represents an advantage
over the traditional solvothermal methods. This approach is prone for industrial applications
due to its easy scale-up [63].
Mechanochemistry is a green, solvent-free and efficient strategy to build MOFs. It is based on
the direct grinding of the linkers and the metal salts either in a mortar or in a ball mill, without
recurring to solvent (neat grinding, NG) or recurring only to catalytic amounts of solvent to
activate the process (liquid-assisted grinding, LAG). Alternatively, also catalytic amounts of
ionic salts can be used to trigger the process (ion- and liquid-assisted grinding, ILAG). This is
a simple method and the absence of solvent makes it very appealing to biomedical applications
[63, 82, 83, 86].
2.3. Loading of drugs and other biomedically relevant compounds into MOFs
The loading of relevant molecules, such as imaging and therapeutic agents, into MOFs can be
done directly during the MOF synthesis or in the postsynthesis.
The direct incorporation implies using those molecules directly to assemble the framework.
This strategy also encloses the networks in which paramagnetic metal ions, such as Gd3+,
Fe3+ and Mn2+, do not act only as the metal sites to connect the ligand but act also as magnetic
resonance imaging contrast agents. High loadings of the relevant compounds can be achieved
by this strategy; however, it is necessary to tune the morphology and physicochemical
properties of these MOFs for each case and it is important to guarantee that there is no
degradation of the compound during the synthesis [21].
The postsynthesis strategy requires high porosity and the active compound is incorporated
within the MOF by noncovalent or covalent interactions. In the case of noncovalent loading,
the process is reversible and therefore the drug release can be premature. On the other hand,
the covalent loading creates a prodrug in which the drug release happens at the same time as
the MOF degradation and thus it may be considered a more robust approach [87].
2.4. Surface modifications
The improved biomedical properties of MOFs also depend on the rational design of the surface.
However, the task of changing the outer surface of the MOF without changing its character‐
istics is still very difficult. Ideally, MOFs should have a coating shell to confer stability to the
material under the different physiological media, but it must be non-toxic and must not
interfere with the pores [86]. There are two approaches to achieve the surface modifications:
covalent and noncovalent attachments. The choice of the best method relies on the parameters
and nature of the MOF, as well as on the nature of the molecule to be grafted [88]. To date only
a few successful examples have been reported of which we highlight the following three.
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A simple, fast and biofriendly method was reported for the use of heparin for the external
functionalization of MIL-100(Fe), preserving all the properties of the MOF. The coating
obtained by this method led to improved biological properties, such as reduced cell recogni‐
tion, lack of complement activation and reactive oxygen species production [89].
The coating of MIL-101(Fe) with a thin film of silica resulted in the prevention of the rapid
degradation of the MOF [87].
Another example of successful coating of MOFs concerns the use of phosphate-modified
biocompatible cyclodextrins. This method was applied to MIL-100(Fe) and resulted in
improved stability in body fluids without interfering with the MOFs properties [90].
3. Applications of BioMOFs: selected examples
The first biomedical applications of nanoscale MOFs were as delivery vehicles for imaging
contrast agents and molecular therapeutics. However, the large amount of paramagnetic metal
ions in these systems further allows their exploration for magnetic resonance imaging (MRI).
[21]. Furthermore, BioMOFs are also being studied as materials for drug storage as well as
controlled drug delivery and release. A few examples of such applications are briefly discussed
and the details of the mentioned BioMOFs are presented in Table 1. For a matter of clarification,
examples of different bio-inspired applications of ZIFs are given in the next section.
3.1. Exploring synergetic effects between metal and drug within a BioMOF
As previously mentioned, one of the best approaches to construct BioMOFs is the direct
incorporation of therapeutically active molecules containing multiple complexing groups with
biocompatible metal cations (Ca2+, Ag2+, Zn2+, Fe2/3+), and thus the delivery of the active
compounds is accomplished via framework degradation [25, 91, 94–97]. Tamames-Tabar et al.
recently discussed the possibility of directly introducing azelaic acid as linker and an endog‐
enous low-toxicity transition metal cation (Zn2+) [98]. Both linker and metal exhibit interesting
antibacterial and dermatological properties for the dermatological treatment of several skin
disorders and their combination results into a novel biocompatible and bioactive MOF, named
BioMIL-5. It was synthesized by hydrothermal methods and its stability was assessed through
tests in water and in bacteria broth at 37°C; also antibacterial activity studies against two Gram-
positive bacteria Staphylococcus aureus and Staphylococcus epidermidis were conducted [91].
In the antibacterial activity studies, the MIC/MBC (MIC = minimal inhibitory concentration;
MBC = minimal bactericidal concentration) values in S. aureus and S. epidermidis demonstrate
that the antimicrobial activity of azelaic acid and Zn2+ is maintained after the synthesis [91].
Regarding the stability tests, BioMIL-5 has shown to be stable in water and in bacterial culture
medium, but especially in water, leading to the progressive release of both Zn2+ and azelaic
acid. Indeed, this progressive and slow release of the active Zn2+ and azelaic acid in both media
led to interesting and time-maintained antibacterial properties when used for 7 days against
S. epidermidis [91]. The high stability demonstrated and the maintenance of its antibacterial
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properties (Figure 1) turn BioMIL-5 into a promising candidate for future applications in the
treatment of several skin disorders and in the cosmetic industry [91].
BioMOF  Metal Ligand  Application  Ref 
BioMIL-5  Zn2+ 
 
Treatment of skin disorders  [93] 
MIL-100  Fe3+ 
 
Drug delivery of ibuprofen  [22, 23] 
MIL-101  Fe3+ 
 
Drug delivery of ibuprofen  [22, 23] 
Bio-MOF-1  Zn2+ 
 
Drug delivery of procainamide HCl  [30] 
MIL-53  Fe3+ 
 
Drug delivery of ibuprofen – “breathing
effects” 
[22] 
CaZol nMOF Ca2+ 
 
Drug delivery of Zol – targeted anticancer
agent 
[94] 
IRMOF-3  Zn2+ 
 
Drug delivery of Paclitaxel – targeted
anticancer agent and MRI applications 
[95] 
Table 1. Details on the presented BioMOFs.
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Figure 1. (Left) Delivery profile of azelaic acid (AzA) and zinc (Zn) in Mueller Hinton cation adjusted broth or MHCA
(M) and in water (W): AzA(M) (pink), AzA(W) (blue), Zn(M) (orange) and Zn(W) (green); (right) Bacterial growth
curves comparing the control group (orange) with BioMIL-5 at different concentrations (mg mL−1): 0.9 (green), 1.7
(blue), and 4.3 mg mL−1 (pink) after 1 week in S. epidermidis (image from Tamames-Tabar et al. [91]—Copyright © 2014,
Royal Society of Chemistry).
3.2. BioMOFs for the controlled drug delivery of ibuprofen
Bearing in mind that BioMOFs are envisaged as new tools for the controlled drug delivery [22,
19-23, 25, 26], Horcajada et al. prepared the first examples of MOFs for the delivery of ibuprofen
in the gastrointestinal tract: MIL-100 (with trimesic acid) and MIL-101 (with terephthalic acid)
[22, 56]. Ibuprofen was chosen as a model drug because it is a worldwide used pharmaceutical
compound with analgesic and antipyretic features [56]. Both MOFs have large pores: MIL-100
contains pore diameters of 25–29 Å with pentagonal window openings of 4.8 Å, and hexagonal
windows of 8.6 Å; MIL-101 contains 29–34 Å pore diameter with a large window opening of
12 Å for the pentagonal and 16 Å for the hexagonal windows. They exhibit a very high drug
storage capacity: up to 0.35 g of ibuprofen per gram of porous solid for MIL-100 and 1.4 g of
ibuprofen per gram of porous solid for MIL-101 [22, 23, 25, 56]. MIL-101 displays a higher
loading capacity due to the fact that ibuprofen can fit in both pentagonal and hexagonal
windows of MIL-101, but not into the smaller pentagonal window of MIL-100 [22, 23, 25]. This
demonstrates the real importance of material’s pore size in drug loading [25, 50]. The kinetics
of ibuprofen delivery to stimulated body fluid at 37°C was also studied, revealing a complete
drug controlled release from 3 to 6 days [22, 23, 25].
3.3. Cation-triggered release of procainamide HCl from BioMOF-1
Another example of a BioMOF constructed by the direct incorporation of simple biomolecules
and biocompatible metal cations in their structures is Bio-MOF-1 proposed by An et al. [30]
Bio-MOF-1 is based on (i) adenine, a purine nucleobase, as a biomolecular ligand, (ii) a second
ligand, biphenyldicarboxylic acid, which was used to promote the formation of larger
accessible pores, and (iii) Zn2+ as a biocompatible metal cation [30]. Bio-MOF-1 has shown to
be stable and maintains its crystallinity for several weeks in biological buffers. Due to the
intrinsic anionic nature of Bio-MOF-1, An et al. explored its potential use as a system for the
storage and release of cationic drug molecules [30], more specifically the storage and release
of procainamide HCl, an effective antiarrhythmic agent used to treat a variety of atrial and
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ventricular dysrhythmias with a short half-life in vivo making necessary its administration
every 3–4 h [29, 30, 99]. Procainamide HCl was successfully encapsulated into the pores of Bio-
MOF-1 through a cation exchange process and the complete loading (0.22 g/g material) was
achieved after 15 days corresponding to approximately 2.5 procainamide molecules per
formula unit residing in the pores and 1 procainamide molecule at the exterior surface [29,
30]. Due to the ionic interaction between procainamide and Bio-MOF-1, cationic drugs are
triggered by cations and then released from the framework. Steady procainamide release was
observed within 20 h and a complete release was observed after 72 h (Figure 2) [30].
Figure 2. (Left) Scheme depicting cation-triggered procainamide release from Bio-MOF-1; (right) procainamide release
profiles from Bio-MOF-1 (blue—PBS buffer; red—deionised nanopure water) (image from An et al. [30]—Copyright ©
2009, American Chemical Society).
3.4. Exploring the potentialities of the breathing effects on BioMOFs
Some MOFs can present structural flexibility or “breathing effects,” which allows them to
modulate their pore size upon adsorption of organic molecules into the pores, while their
crystallinity is maintained [22, 50, 54, 59]. One example of BioMOFs presenting a “breathing
effect” is MIL-53 [22, 54, 100]. The structure of MIL-53 consists on terephatalate anions and
trans-chains of metal (III) octahedra sharing OH groups and thus creating a 3D framework
with one-dimensional pore channel systems [22, 100]. The capacity to expand its structure upon
heating explains the ``breathing effect’’ observed in MIL-53 (Figure 3) [22]. In this study,
Horcajada et al. also observed that aluminium and chromium MIL-53lt (lt is low temperature)
present a reversible pore opening involving atomic displacements by 5.2 Å upon dehydration,
whereas the iron analogue only open its pores during the adsorption molecules [101, 102]. This
can be explained by the formation of hydrogen bonds between the water molecules and the
inorganic hydrophilic parts of the pore. After approximately 3 weeks, a complete release of
ibuprofen is observed, where 20 wt% of ibuprofen loading was achieved at high temperature
(Figure 3) [22].
3.5. pH-responsive BioMOFs
An interesting example that shows the potential use of BioMOFs in biomedical applications is
the recently disclosed work of Au et al. which is based on the reformulation of zoledronate
(Zol) exploring nanotechnology to develop a new nanoscale MOF (nMOFs) formulation of Zol,
turning a bone antiresorptive agent into an anticancer agent [92].
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Zol is a third-generation nitrogen heterocycle containing bisphosphonate that is widely used
as an antiresorptive agent for bone cancer metastasis. In the preclinical data, it was observed
that bisphosphonates such as Zol have direct cytotoxic effects on cancer cells. However, such
effect has not been firmly established in the clinical settings, what led Au et al. to develop a
new bioresorbable sub-100 nm diameter pH-responsive calcium zoledronate (CaZol) nMOF
as a potential cytotoxic anticancer agent. Folate receptor (FR) is known to be overexpressed in
tumours, and therefore folate (Fol) was incorporated as a target ligand into the CaZol nMOFs
to facilitate tumour uptake. This study successfully demonstrated that the active-targeted
CaZol nMOF possesses excellent chemical and colloidal stability on physiological conditions,
encapsulating more Zol than other existing drug delivery systems. It further shows higher
efficiency than small molecule Zol in inhibiting cell proliferation and inducing apoptosis in
FR-overexpressing H460 non-small cell lung and PC3 prostate cancer cells in vitro. Au et al.
also validated these results in vivo and observed that Fol-targeted CaZol nMOF proved to be
an effective anticancer agent, increasing the direct antitumour activity of Zol by 80–85% [92].
3.6. Magnetic nanoscale MOF as potential anticancer drug delivery system, and imaging
and MRI contrast agent
The combination of both imaging and therapeutic agents in the same MOF greatly facilitates
the efficacy studies of theranostic nanoparticles. Having this in mind, Chowdhuri et al.
developed a new magnetic nanoscale MOF (IRMOF-3) consisting of a MOF with encapsulated
Figure 3. (Top) Schematic 3D representation of the breathing effect of MIL-53(Cr) hybrid solid upon dehydration-hy‐
dration; (bottom) ibuprofen delivery (left) from MIL-53(Cr) and MIL-53(Fe) materials and (right) from MIL-53 in com‐
parison with MIL-101, MCM-41 and MCM-4 (images from Horcajada et al. [22]—Copyright © 2008, American
Chemical Society).
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Fe3O4 nanoparticles for targeted anticancer drug delivery with cell imaging and magnetic
resonance imaging (MRI). More specifically, authors conjugated the magnetic nanoscale MOF
with folic acid and labelled it with the fluorescent molecule rhodamine B isothiocyanate due
to its fluorescent properties. These systems were then successfully loaded with the hydropho‐
bic anticancer drug paclitaxel. The efficiency of this nMOF towards targeted drug delivery was
evaluated using an in vitro cytotoxicity 5-diphenyltretrazolium bromide (MTT) assay and
fluorescence microscopy, revealing that the loaded nMOF targeted and killed the cancer cells
in a highly effective manner. Furthermore, they had also tested the effectiveness of MRI of this
nMOF in vitro and observed a stronger T2-weighted MRI contrast towards the cancer cells,
which proved the possible use of this system in imaging (Figure 4) [93].
Figure 4. (Left) In vitro T2-weighted spin-echo MR phantom images of magnetic nanoscale Fe3O4@IRMOF-3 and mag‐
netic nanoscale Fe3O4@IRMOF-3/FA at different concentrations incubated in HeLa cells; (right) in vitro paclitaxel re‐
lease from magnetic nanoscale Fe3O4@IRMOF-3/FA at different time intervals (images from Chowdhuri et al. [93]—
Copyright © 2015, Royal Society of Chemistry).
4. Bio-inspired applications of ZIFs: selected examples
There are many applications for ZIFs, specifically ZIF-8 (Figure 5). However, this type of
materials has largely been explored as a way to deliver anticancer drugs and other chemo‐
therapeutics. Only a few relevant examples are mentioned herein.
Figure 5. (a) Synthesis of ZIF-8; (b) fragment of the crystal structure of ZIF-8 (images adapted from Katsenis et al. [103]
—Copyright © 2015, Rights Managed by Nature Publishing Group); and (c) image generated for ZIF-8 in http://
www.chemtube3d.com (University of Liverpool).
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4.1. Slow release of the anti-cancer drug doxorubicin from ZIF-8
Zheng et al. successfully developed a simple one-pot synthesis of ZIFs that contain encapsu‐
lated organic molecules. One-pot synthesis is a new approach that combines MOF synthesis
and molecule encapsulation in a one-pot process and that has been extremely used to overcome
the drawbacks observed when using the two processes separately [104].
In this study, the doxorubicin: ZIF-8 complex, which aims to treat mucoepidermoid carcinoma
of human lung, human colorectal adenocarcinoma (HT-29) and human promyelocytic
leukaemia (HL-60) cell lines, exhibits lower toxicity than pure doxorubicin, probably due to
the slow release of the drug that is achieved with this complex (Figure 6) [69, 104]. Furthermore,
ZIF-8 crystals loaded with doxorubicin proved to be efficient pH-responsive drug delivery
systems, in which the drug is released in a controlled manner at low pH (5.0–6.5). With this
work, Zheng et al. opened a new opportunity to develop multifunctional materials for
biomedical applications using this simple, scalable, and environment-friendly one-pot
synthesis [104].
Figure 6. (Top) Schematic representation of the pH-induced one-pot synthesis of MOFs with encapsulated target mole‐
cules; (bottom left) The pH-responsive release of doxorubicin from doxorubicin@ZIF-8 particles determined by UV-vis
spectrophotometry; (bottom right) TEM image of an MDA-MB-468 cell; and the inset is an enlarged image of the area
marked by the square showing individual ZIF-8 particles (blue arrows) and their aggregates (red arrows) (image from
Zheng et al. [104]—Copyright © 2016, American Chemical Society).
4.2. ZIF-8 as efficient pH-sensitive drug delivery
“Smart” drug delivery of anticancer drugs is being explored making use of pH-sensitive
systems [65–68]. The interest in the use of a pH-responsive drug vehicle is due to the fact that
they can reduce undesired drug release during transportation in blood circulation and improve
the effective release of the drug in the tumour tissue or within tumour cells [105, 106].
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Sun et al. evaluated the possibility to use ZIF-8 as a pH-responsive drug vehicle and they have
demonstrated that ZIF-8 exhibits a remarkable loading capacity for the anticancer drug 5-
fluorouracil (around 600 mg of 5 FU g−1 of desolvated ZIF-8) (Figure 7) [66]. Ren et al. further
developed polyacrylic acid@ZIF-8 (PAA@ZIF-8) nanoparticles that exhibit ultrahigh doxoru‐
bicin loading capability (1.9 g doxorubicin/g nanoparticles) and that thus can be used as pH-
dependent drug delivery vehicles [65].
Figure 7. (Left) Schematic illustration showing two approaches of the encapsulated 5-Fu released from ZIF-8 (C = grey,
N = blue, O = red, F = light blue, Zn = green); (right) 5-Fu delivery (% 5-FU vs. t) from ZIF-8; the inset shows the release
process from 0 to 24 h (images from Sun et al. [66]—Copyright © 2012, Royal Society of Chemistry).
Figure 8. Schematic representation of the synthetic route of the C-dots@ZIF-8 for simultaneous anticancer drug deliv‐
ery and fluorescence imaging of cancer cell (image from He et al. [67]—Copyright © 2014, Royal Society of Chemistry).
Zhuang et al. successfully encapsulated small molecules, such as fluorescein and the anticancer
drug camptothecin, in ZIF-8 nanospheres for drug delivery. In this study, the evaluation of
fluorescein-encapsulated ZIF-8 in the MCF-7 breast cancer line demonstrated cell internaliza‐
tion and a minimal cytotoxicity. Furthermore, the pH-responsive dissociation of the ZIF-8
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framework likely results in endosomal release of the small-molecule cargo proved that ZIF-8
can be an ideal drug delivery vehicle [68].
Another example of a pH-responsive drug vehicle using ZIF-8 is the work of Liu et al., who
fabricate green fluorescent carbon nanodots@ZIF-8 (c-dots@ZIF-8 NPs). In this work, the
authors observed that the nanoparticles synthesized exhibit green fluorescence and micro‐
porosity, characteristics that unveil its ability as potential platforms for simultaneous pH-
responsive anticancer drug vehicle and fluorescence imaging in cancer cells (Figure 8).
Moreover, the fluorescence intensity and size of c-dots@ZIF-8 NPs can be tuned by varying
the amount of C-dots and the concentration of the precursors [67].
4.3. ZIFs as potential carriers to brain capillary endothelial cells
One extraordinary example of the biomedical applications of ZIFs is the recent work from
Chiacchia et al. who synthesized and characterized nanospheres of biodegradable zinc-
imidazolate polymers (ZIPs) as a delivery system into human brain endothelial cells, the main
component of the blood-brain barrier (BBB) [107].
Figure 9. Synthesis and assembly of loaded ZIP particles and their uptake into human brain endothelial cells: (I) encap‐
sulation process of cargo species into the ZIP matrices at the point of synthesis; (II) cross-section of the human cerebral
microvasculature and cell-uptake of loaded ZIP particles by the isolated and immortalized human brain endothelial
cell line (image from Chiacchia et al. [107]—Published by The Royal Society of Chemistry).
In this work, both biodegradable particles synthesized, RhB@ZIP and AuNP@ZIP, have shown
to be able to encapsulate fluorophores and inorganic nanoparticles at the point of synthesis
with extremely high loading efficiencies. Furthermore, these ZIP particles are non-cytotoxic,
stable in cell culture medium and able to penetrate the hCME\D3 human cerebral microvas‐
cular endothelial cell line. This cell line is a well-established in vitro functional model for the
human BBB, which expresses the same levels of transporters, cell-specific receptors and tight
junction proteins found in healthy human brain microvessels [108, 109], to release their cargos
within the cell cytoplasm (Figure 9) [107].
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Nevertheless this work needs more studies related to the exact cellular uptake mechanism,
clearance rate and blood-stream stability of the ZIPs, but this is a promising result in the use
of ZIPs as a novel platform for brain-targeting treatments [107].
5. Final remarks
Bio-inspired metal-organic frameworks have already proven to have promising biomedical
applications not only as drug delivery systems but also in magnetic resonance imaging (MRI),
optical imaging and X-ray computed tomography (CT) imaging.
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